Metformin, which has typically been used to treat type 2 diabetes mellitus, has also been explored for its anti-inflammatory potential in patients with systemic lupus erythematosus (SLE). Rheumatologist and lupus expert Dr. Mithu Maheswaranathan spoke with DocWire News about a recent study that shows metformin is a promising complementary therapy for SLE, and how the results can better inform care in rheumatology.